WuXi AppTec Co., Ltd. (HKG:2359)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
111.20
-4.40 (-3.81%)
At close: Jan 30, 2026
101.45%
Market Cap319.14B +99.9%
Revenue (ttm)47.96B +23.2%
Net Income16.39B +85.9%
EPS5.09 +53.2%
Shares Outn/a
PE Ratio19.48
Forward PE18.12
Dividend1.82 (1.59%)
Ex-Dividend DateSep 8, 2025
Volume4,387,409
Average Volume6,349,256
Open112.90
Previous Close115.60
Day's Range110.60 - 115.10
52-Week Range44.30 - 124.70
Beta0.67
RSI49.42
Earnings DateMar 24, 2026

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecula... [Read more]

Sector Healthcare
Founded 2000
Employees 37,832
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2359
Full Company Profile

Financial Performance

In 2024, WuXi AppTec's revenue was 37.92 billion, a decrease of -1.97% compared to the previous year's 38.68 billion. Earnings were 9.45 billion, a decrease of -1.63%.

Financial numbers in CNY Financial Statements